Literature DB >> 2837240

Topoisomerases: novel therapeutic targets in cancer chemotherapy.

Y H Hsiang1, H Y Wu, L F Liu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2837240     DOI： 10.1016/0006-2952(88)90453-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  10 in total

Review 1.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

2.  mRNA expression of topoisomerase II in human tumors and normal tissues.

Authors:  R Kim; N Hirabayashi; M Nishiyama; T Yorishima; T Toge; K Okada
Journal:  Jpn J Surg       Date:  1991-09

3.  Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer.

Authors:  Nilesh A Patankar; Dawn Waterhouse; Dita Strutt; Malathi Anantha; Marcel B Bally
Journal:  Invest New Drugs       Date:  2012-05-22       Impact factor: 3.850

4.  Pharmacokinetics and toxicity of two modalities of etoposide infusion in metastatic non-small-cell lung carcinoma.

Authors:  E Chatelut; C Chevreau; E Blancy; A Lequellec; P Canal; H Roche; G Houin; R Bugat
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  DNA topoisomerases from pathogenic fungi: targets for the discovery of antifungal drugs.

Authors:  L L Shen; J Baranowski; J Fostel; D A Montgomery; P A Lartey
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

6.  A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma.

Authors:  F Mühr-Wilkenshoff; W Hinkelbein; I Ohnesorge; K J Wolf; E-O Riecken; M Zeitz; H Scherübl
Journal:  Int J Colorectal Dis       Date:  2003-02-01       Impact factor: 2.571

7.  Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice.

Authors:  Y Kawato; T Furuta; M Aonuma; M Yasuoka; T Yokokura; K Matsumoto
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

8.  Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation.

Authors:  Euan Ramsay; Jehan Alnajim; Malathi Anantha; Aman Taggar; Anitha Thomas; Katarina Edwards; Göran Karlsson; Murray Webb; Marcel Bally
Journal:  Pharm Res       Date:  2006-10-25       Impact factor: 4.580

9.  Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers.

Authors:  Reza Ehsanian; Carter Van Waes; Stephan M Feller
Journal:  Cell Commun Signal       Date:  2011-05-15       Impact factor: 5.712

Review 10.  Dual Inhibitors Against Topoisomerases and Histone Deacetylases.

Authors:  Young Ho Seo
Journal:  J Cancer Prev       Date:  2015-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.